Lengyel Mária
Gottsegen György Országos Kardiológiai Intézet, Budapest.
Orv Hetil. 2004 Dec 26;145(52):2619-21.
A SPORTIF-III substudy.
Warfarin has been considered to provide more stable anticoagulant effect than acenocoumarol due to its longer half-life.
The aim of this SPORTIF-III substudy was to compare acenocoumarol (A) with warfarin (W) in the same group of 74 patients, with chronic atrial fibrillation who started with W and then changed to A.
We compared prospectively a 3 months period on W with a 3 months period on A.
The mean number of INR measurements per patient was 5.7 +/- 1.2 and 5.4 +/- 1.6 resp (NS). The mean percentage of INR-s in the therapeutic range of 2-3 was 49 +/- 22.6% for W and 56 +/- 26.8% for A (p < 0.05), the percentage of subtherapeutic values were not different, the supratherapeutic values however occurred more frequently on W (28 +/- 20%) than on A (19 +/- 19%), p < 0,001. There was a good correlation between A and W doses (r = 0.65, p < 0.001), the mean W dose was 5.03 +/- 1.99 mg, the mean A dose was 2.5 +/- 1.3 mg, the W/A dose ratio was computed to be 2.18 +/- 0.78.
一项SPORTIF - III子研究。
由于华法林半衰期较长，一直被认为比醋硝香豆素具有更稳定的抗凝效果。
这项SPORTIF - III子研究的目的是在74例慢性房颤患者中比较醋硝香豆素（A）与华法林（W），这些患者先使用W，然后改用A。
我们前瞻性地比较了使用W的3个月时期与使用A的3个月时期。
每位患者INR测量的平均次数分别为5.7±1.2和5.4±1.6（无显著性差异）。INR在2 - 3治疗范围内的平均百分比，W为49±22.6%，A为56±26.8%（p < 0.05），低于治疗值的百分比无差异，然而高于治疗值在W（28±20%）比在A（19±19%）更频繁出现，p < 0.001。A和W剂量之间有良好的相关性（r = 0.65，p < 0.001），W的平均剂量为5.03±1.99毫克，A的平均剂量为2.5±1.3毫克，W/A剂量比经计算为2.18±0.78。
